Owkin partners with Istituto Europeo di Oncologia (IEO) to advance AI-driven cancer research and therapeutic development

• IEO ranks among the world's top cancer research institutes with over 18,000 patients served annually
• Partnership will leverage AI to identify and validate new biomarkers and therapeutic targets
• Collaboration includes comprehensive research initiatives and potential integration of AI tools into clinical workflows

Paris, Milan, 9/17/2025 - Owkin and Istituto Europeo di Oncologia (IEO) have announced a strategic partnership to advance AI-driven cancer research and accelerate the development of innovative diagnostic and therapeutic solutions.

The collaboration will leverage Owkin's agentic AI capabilities and IEO's world-class clinical expertise and extensive multimodal datasets to develop and validate AI solutions that could transform cancer diagnosis and treatment for patients.

"AI is revolutionizing how we approach cancer research, but the true value comes from validating these discoveries with world-class clinical partners. IEO's exceptional expertise in oncology and commitment to innovation makes them an ideal partner to translate our AI findings into meaningful advances for patients," said Francisco Miguel Torres, Partnerships Director at Owkin.

"This partnership with Owkin represents an important step forward in applying cutting-edge AI to improve patient outcomes. By combining our clinical expertise with Owkin's innovative AI platform, we aim to accelerate the development of tools that can provide more precise and targeted treatment strategies for our patients," said Prof. Nicola Fusco, Director of the Division of Pathology, European Institute of Oncology IRCCS.

This collaboration strengthens Owkin's presence in Italy's vibrant oncology research ecosystem and demonstrates the commitment of both organizations to bringing AI-powered solutions to patients globally.

As cancer cases continue to rise worldwide, partnerships that combine AI innovation with clinical excellence become increasingly critical for advancing treatment options and improving patient outcomes.

About Istituto Europeo di Oncologia (IEO)

IEO is one of Italy's leading cancer research institutes and a key player in oncology worldwide. With 307 beds, over 18,000 patients served annually, and 698 active clinical trials, IEO combines cutting-edge research with exceptional patient care. The institute is recognized globally for its contributions to cancer research and innovative treatment approaches.

For further information: https://www.ieo.it/